DexCom, Inc. (NASDAQ: DXCM) disclosed Friday that the FDA's panel of the Clinical Chemistry and Clinical Toxicology Devices voted in favor of its planned non-adjunctive indication for its G5 Mobile ...
Despite a more than 35 percent plunge in DexCom, Inc. (NASDAQ: DXCM)'s stock, analysts at Canaccord Genuity continue to hold a bullish outlook. The firm's Kyle Rose maintains a Buy on DexCom's stock ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Dexcom announced ...
DexCom Inc. DXCM and Abbott Laboratories ABT are likely to launch their first over-the-counter (OTC) continuous glucose monitors (CGMs) in the coming months of 2024. Dexcom’s Stelo and Abbott’s Lingo ...
Worldcategory US slashes 'de minimis' tariff on small China parcels to as low as 30% 9:15 PM UTC Worldcategory Trump says US to lift Syria sanctions, secures $600 billion Saudi deal 10:39 PM UTC Macro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback